Patients with myasthenia gravis (MG) face a high prevalence of low bone mineral density (BMD), with 43.5% of individuals showing skeletal alterations, according to a cross-sectional study published in Arquivos de Neuro-Psiquiatria. Researchers led by Renata Dal-Prá Ducci found that age, rather than corticosteroid use or disease severity, serves as a primary independent predictor for bone health decline in this patient population.
Understanding the Bone Health Risks in Myasthenia Gravis
While long-term corticosteroid use is a known risk factor for bone loss in many chronic conditions, the study from the Neuromuscular Diseases Service at the Hospital de Clínicas, Universidade Federal do Paraná, suggests the picture is more complex for MG patients. Among the 92 participants evaluated between 2018 and 2022, nearly 95% had a history of corticosteroid treatment. Despite this high exposure, statistical analysis did not reveal a direct correlation between current drug regimens and lower BMD.
Instead, age emerged as the most significant factor. The study identified a cutoff age of 49 years; patients at or above this threshold showed a notably higher risk of BMD alterations. With 33% of the cohort classified as high-risk for fractures via the FRAX tool, the data highlights a clear need for proactive skeletal monitoring in middle-aged and older MG patients.
Did you know?
The study found that while most patients reported adequate calcium intake, they struggled to maintain regular physical exercise—a key component of bone density maintenance—suggesting that lifestyle interventions may be underutilized in MG management.
Shifting Toward Proactive Screening Protocols
The findings suggest that the current clinical approach to myasthenia gravis may need to expand beyond symptom control. Because 8% of the study participants had already experienced fragility fractures, researchers argue that bone health screening should be integrated into routine care for all patients over 49, regardless of how severe their MG symptoms appear to be.
The diagnostic protocol used in the study—utilizing GE Lunar densitometers to assess the lumbar spine and proximal femur—provides a blueprint for how clinics can better identify “silent” bone loss before it results in a fracture. By focusing on age as a primary screening trigger, clinicians can potentially improve long-term outcomes for patients who might otherwise be overlooked due to a perceived lack of corticosteroid-related risk.
Future Trends in MG and Bone Density Management
The data indicates that relying solely on drug history is insufficient for predicting who will develop osteoporosis.
By identifying high-risk patients earlier, healthcare providers can implement preventative measures before the onset of symptomatic bone disease.
Pro Tip: Managing Bone Health
If you are living with myasthenia gravis, ask your neurologist about a baseline bone density scan (DXA) once you reach age 49. Discussing a tailored exercise plan that accounts for your muscle fatigue levels is also a critical step in preserving bone mass.
Frequently Asked Questions
Does corticosteroid use definitely cause bone loss in MG patients?
While corticosteroids are generally associated with reduced bone mass, this specific study found no independent correlation between corticosteroid use and BMD alterations among the MG patients observed. Age was a much stronger predictor.
What age should patients start screening for bone density?
The study identified 49 years of age as a significant cutoff point where BMD alterations become more prevalent, suggesting that screening should be prioritized for patients in this age group and older.
Why is physical activity important for MG patients?
Regular exercise is essential for maintaining bone mineral density. The study noted that many MG patients lack sufficient physical activity, which may contribute to the high prevalence of low BMD, independent of their disease severity or medication history.
Are you or a loved one managing myasthenia gravis? We want to hear about your experience with bone health monitoring. Share your thoughts in the comments below or subscribe to our newsletter for the latest updates on neuromuscular disease research.
